Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapagliflozin Reduces the Progression of Chronic Kidney Disease in Lupus Nephritis: Phase II Trial.

NCT07678203 is registered in ClinicalTrials.gov with Hospital Civil Juan I. Menchaca as lead sponsor.

NCT NCT07678203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07678203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapagliflozin Reduces the Progression of Chronic Kidney Disease in Lupus Nephritis: Phase II Trial.
Lead sponsor
Hospital Civil Juan I. Menchaca
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 28, 2026
Completion date
February 26, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, lupus nephritis (ln), sglt 2 inhibitors, systemic lupus erythematosus